Europe Gene Therapy Market to Hit $8,780.77 Million by 2033 | Viral vectors dominate with 74% share owing to high efficiency and strong use of AAV and lentiviral platforms

Leander, Texas and Tokyo, Japan - Nov.27.2025
As per DataM intelligence research report" Europe Gene Therapy Market reached US$ 1,030.70 Million in 2024 and is expected to reach US$ 8,780.77 Million by 2033, growing at a CAGR of 24.9 % during the forecast period 2025-2033." Breakthroughs in genetic engineering and regulatory support are advancing gene therapy development across Europe.

Download your exclusive sample report today: (corporate email gets priority access):
https://www.datamintelligence.com/download-sample/europe-gene-therapy-market?Prasad

Europe: Recent Industry Developments

✅ In November 2025, Novartis advanced gene-therapy trials targeting rare neurological disorders in Europe. The progress improves therapeutic precision. This strengthens Novartis' leadership in genomic medicine.

✅ In October 2025, Roche expanded viral-vector manufacturing capabilities to support large-scale gene therapy delivery. The upgrade improves supply reliability. This reinforces Roche's manufacturing strength.

✅ In September 2025, UniQure progressed European trials for hemophilia gene therapy with improved dosing protocols. The update boosts treatment durability. This enhances UniQure's clinical impact.

✅ In August 2025, Orchard Therapeutics initiated CRISPR-based clinical trials for inherited metabolic disorders in Europe. The trials advance personalized therapy approaches. This strengthens Orchard's research footprint.

✅ In July 2025, BioMarin expanded AAV vector production facilities for rare disease gene therapies. The enhancement increases production capacity. This reinforces BioMarin's European market readiness.

✅ In June 2025, Pfizer Gene Therapy advanced precision dosing strategies for muscular dystrophy treatments. The innovation improves patient safety and efficacy. This strengthens Pfizer's gene-therapy portfolio.

Europe Gene Therapy Market: Drivers
The Europe gene therapy market is growing rapidly as advancements in genetic engineering, viral vectors, and precision medicine drive the development of breakthrough treatments. Gene therapies targeting rare diseases, cancers, and inherited disorders are gaining regulatory approvals and attracting major investments. Strong clinical research infrastructure, biotechnology innovation, and supportive regulatory pathways are accelerating product development. Advancements in CRISPR technology, vector optimization, and targeted delivery systems are enhancing safety and therapeutic outcomes. Additionally, increased government funding and cross-border scientific collaboration are strengthening market growth.

Collaboration among biotech companies, academic institutions, and pharmaceutical innovators is driving expansion of clinical pipelines and commercial manufacturing capabilities. Growing availability of advanced therapies, reimbursement support for life-saving treatments, and rising patient awareness are improving adoption. Investments in biomanufacturing facilities, viral vector production, and regulatory harmonization are enhancing Europe's competitiveness. With increasing innovation, expanding therapeutic applications, and strong policy support, the Europe gene therapy market is positioned for significant long-term advancement.

Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/europe-gene-therapy-market?Prasad

Europe Gene Therapy Market: Major Players
Alnylam Pharmaceuticals, Inc., NOVARTIS AG, Sarepta Therapeutics, Inc., Krystal Biotech, Inc., CSL, Bluebird Bio, Inc., SPARK THERAPEUTICS, INC., Ferring, Vertex Pharmaceuticals Incorporated, Amgen, Inc., Orchard Therapeutics Plc, CRISPR Therapeutics, BioMarin Pharmaceutical Inc., MeiraGTx Holdings plc, and PTC Therapeutics, Inc. among others.

Segment Covered in the Europe Gene Therapy Market:
By Approach
In-vivo gene therapy leads with 62% share as Europe accelerates approval of directly administered therapies for rare diseases and oncology. Ex-vivo approaches hold 38%, driven by CAR-T cell therapies and hematologic disorder treatments. Both segments benefit from advanced clinical pipelines.

By Vector Type
Viral vectors dominate with 74% share owing to high efficiency and strong use of AAV and lentiviral platforms. Non-viral vectors represent 26%, supported by rising interest in lipid nanoparticles and plasmid-based delivery. Regulatory acceptance of safer vectors boosts overall adoption.

By Technique
Gene addition holds 48% share, driven by therapies targeting monogenic disorders and inherited deficiencies. Gene silencing accounts for 27%, supported by emerging RNA-based and antisense technologies. Gene editing contributes 25%, led by CRISPR advancements and pipeline growth in Europe.

By Application
Rare diseases dominate with 41% share as funding, regulatory incentives, and unmet needs accelerate adoption. Oncology holds 32%, driven by expanding CAR-T approvals and immuno-oncology research. Musculoskeletal, blood disorders, ophthalmology, and others collectively represent 27%, supported by targeted therapeutic development.

Regional Analysis
Western Europe (Market Share: 46%)
Western Europe leads with 46% share, driven by strong biotech hubs in Germany, France, and the UK. High R&D investment and early clinical adoption support growth. Advanced regulatory pathways accelerate commercialization.

Northern Europe (Market Share: 22%)
Northern Europe holds 22% share, supported by strong healthcare infrastructure and high genetic-disorder diagnosis rates. Scandinavian countries lead in clinical trials. Robust funding ecosystems fuel innovation.

Southern Europe (Market Share: 18%)
Southern Europe accounts for 18% share with rising adoption in Italy and Spain. Improved reimbursement systems boost therapy access. Growing oncology-focused trials strengthen regional momentum.

Eastern Europe (Market Share: 14%)
Eastern Europe holds 14% share, driven by improving healthcare investment and rising rare disease awareness. Adoption is slower but expanding via cross-border treatment programs. Emerging clinical trial sites contribute to steady growth.

Purchase this report before year-end and unlock an exclusive 30% discount:
https://www.datamintelligence.com/buy-now-page?report=europe-gene-therapy-market
(Purchase 2 or more Repots and get 50% Discount)

Request for 2 Days FREE Trial Access:
https://www.datamintelligence.com/reports-subscription?Prasad

✅ Competitive Landscape
✅ Technology Roadmap Analysis
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Consumer Behavior & Demand Analysis
✅ Import-Export Data Monitoring
✅ Live Market & Pricing Trends

Have a look at our Subscription Dashboard:
https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.